Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMT1OAH)

Drug Name
SCH-23390 Drug Info
Synonyms
Sch-23388; Lopac-D-054; AC1O7G1X; GTPL956; CHEMBL63321; SCH 23388 (S-enantiomer); SCHEMBL11107859; BDBM82248; GOTMKOSCLKVOGG-HNNXBMFYSA-N; ZINC2017840; PDSP1_001624; PDSP2_001608; PDSP2_000613; PDSP1_000616; NCGC00015301-01; (+)-SCH-23390; CAS_73445-63-3; (5S)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol; (1S)-7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol
Cross-matching ID
PubChem CID
5018
ChEBI ID
CHEMBL13668
TTD Drug ID
D0L8PI

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.15 0.00e+0 34/36 (94.44%) MCM6;MCM4;MCM5;...
Ribosome 2.12 0.00e+0 113/158 (71.52%) RPL35;RPL14;MRPL11;...
Dilated cardiomyopathy 2.12 0.00e+0 86/96 (89.58%) TNNC1;GNAS;TTN;...
Hypertrophic cardiomyopathy 2.03 1.78e-3 81/90 (90%) TNNC1;TTN;CACNA2D2;...
Base excision repair 1.99 1.43e-3 29/33 (87.88%) POLE3;FEN1;POLD1;...
Cardiac muscle contraction 1.95 2.38e-3 64/87 (73.56%) TNNC1;CACNA2D2;TPM3;...
Homologous recombination 1.94 2.04e-3 35/41 (85.37%) RAD51;POLD1;TOPBP1;...
Fanconi anemia pathway 1.89 7.14e-3 36/54 (66.67%) MLH1;RAD51;FANCI;...
Cell cycle 1.87 6.35e-3 110/124 (88.71%) CHEK1;MAD2L1;CDC20;...
Sulfur metabolism 1.77 1.43e-2 9/10 (90%) SELENBP1;SUOX;TST;...
Mismatch repair 1.73 2.08e-2 22/23 (95.65%) MLH1;RFC5;MSH2;...
Tyrosine metabolism 1.69 2.74e-2 30/36 (83.33%) ADH1B;DBH;GSTZ1;...
Adrenergic signaling in cardiomyocytes 1.63 4.45e-2 130/150 (86.67%) TNNC1;GNAS;CACNA2D2;...
Glycine, serine and threonine metabolism -1.63 3.28e-2 31/40 (77.5%) AOC3;PIPOX;GNMT;...
Mitophagy -1.64 3.39e-2 56/68 (82.35%) OPTN;SRC;RHOT2;...
Bacterial invasion of epithelial cells -1.65 3.03e-2 59/77 (76.62%) ARPC5;ACTR2;RAC1;...
Proteoglycans in cancer -1.65 3.10e-2 172/205 (83.9%) MYC;PTPN6;SMO;...
Endocytosis -1.65 3.22e-2 198/252 (78.57%) CHMP2A;RABEP1;RAB11FIP3;...
Salmonella infection -1.66 3.25e-2 198/249 (79.52%) AKT3;CYTH2;DYNLT3;...
Fructose and mannose metabolism -1.66 3.19e-2 30/33 (90.91%) HK1;PFKL;ALDOA;...
Yersinia infection -1.67 3.06e-2 120/137 (87.59%) SRC;ITGA4;PKN2;...
Shigellosis -1.68 3.14e-2 180/246 (73.17%) CTTN;MAPK11;CUL1;...
Complement and coagulation cascades -1.71 2.37e-2 76/85 (89.41%) VWF;CD59;CFHR2;...
Tuberculosis -1.73 2.06e-2 159/180 (88.33%) CR1;CAMK2A;SRC;...
Graft-versus-host disease -1.73 2.11e-2 32/42 (76.19%) KLRD1;KIR2DL1;HLA-DPB1;...
Porphyrin and chlorophyll metabolism -1.74 1.96e-2 23/43 (53.49%) HCCS;CPOX;UGT2B4;...
Other glycan degradation -1.74 2.07e-2 13/18 (72.22%) MAN2C1;MAN2B2;ENGASE;...
Toxoplasmosis -1.76 1.59e-2 103/112 (91.96%) MYD88;MAP2K3;HSPA8;...
Biosynthesis of unsaturated fatty acids -1.78 1.21e-2 21/27 (77.78%) ELOVL1;FADS1;SCP2;...
Lysosome -1.79 9.53e-3 115/128 (89.84%) CTSH;CD63;ABCA2;...
Rheumatoid arthritis -1.82 3.73e-3 78/93 (83.87%) ATP6V0A4;TLR2;VEGFA;...
Synaptic vesicle cycle -1.85 4.04e-3 63/78 (80.77%) ATP6V0A4;NSF;ATP6V1H;...
HIF-1 signaling pathway -1.86 4.41e-3 105/109 (96.33%) IFNG;FLT1;PDK1;...
Autoimmune thyroid disease -1.88 4.85e-3 46/53 (86.79%) TSHR;HLA-DOB;HLA-DPA1;...
Type I diabetes mellitus -1.92 2.70e-3 38/43 (88.37%) HLA-DOB;HLA-DPA1;CD86;...
Protein processing in endoplasmic reticulum -1.95 1.52e-3 127/171 (74.27%) NGLY1;SEC63;SSR3;...
Allograft rejection -1.95 1.73e-3 32/38 (84.21%) HLA-DOB;HLA-DPA1;CD86;...
Epithelial cell signaling in Helicobacter pylori infect... -1.98 2.02e-3 62/70 (88.57%) CXCR1;JAM2;CSK;...
Ferroptosis -2.05 0.00e+0 36/41 (87.8%) ACSL3;NCOA4;ACSL6;...
Leishmaniasis -2.12 0.00e+0 67/77 (87.01%) JUN;MYD88;ELK1;...
Phagosome -2.13 0.00e+0 118/152 (77.63%) ITGB1;HLA-DOB;ATP6V0A1;...
Antigen processing and presentation -2.13 0.00e+0 60/78 (76.92%) IFI30;NFYA;HSPA8;...
Collecting duct acid secretion -2.18 0.00e+0 22/27 (81.48%) ATP6V0A1;TCIRG1;ATP6V0E1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H